E-mail

E-mail a Wiley Online Library Link

A. Vahlquist, S. Blockhuys, P. Steijlen, K. van Rossem, B. Didona, D. Blanco and H. Traupe Oral liarozole in the treatment of patients with moderate/severe lamellar ichthyosis: results of a randomized, double-blind, multinational, placebo-controlled phase II/III trial British Journal of Dermatology 170

Article first published online: 13 JAN 2014 | DOI: 10.1111/bjd.12626

What's already known about this topic?

  • Oral liarozole, a retinoic acid metabolism-blocking agent, may be an alternative to systemic retinoid therapy for patients with lamellar ichthyosis.

What does this study add?

  • While the primary endpoint was not met, compared with placebo, once-daily oral liarozole, 75 or 150 mg, decreased overall severity and scaling, but not erythema and pruritus, and improved Dermatology Life Quality Index in patients with lamellar ichthyosis.
  • Oral liarozole was well tolerated.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH